1. Home
  2. ZYME vs OSBC Comparison

ZYME vs OSBC Comparison

Compare ZYME & OSBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZYME
  • OSBC
  • Stock Information
  • Founded
  • ZYME 2003
  • OSBC 1981
  • Country
  • ZYME United States
  • OSBC United States
  • Employees
  • ZYME N/A
  • OSBC N/A
  • Industry
  • ZYME Biotechnology: Pharmaceutical Preparations
  • OSBC Major Banks
  • Sector
  • ZYME Health Care
  • OSBC Finance
  • Exchange
  • ZYME Nasdaq
  • OSBC Nasdaq
  • Market Cap
  • ZYME 968.5M
  • OSBC 804.3M
  • IPO Year
  • ZYME 2017
  • OSBC N/A
  • Fundamental
  • Price
  • ZYME $15.93
  • OSBC $18.04
  • Analyst Decision
  • ZYME Buy
  • OSBC Buy
  • Analyst Count
  • ZYME 7
  • OSBC 6
  • Target Price
  • ZYME $20.00
  • OSBC $20.08
  • AVG Volume (30 Days)
  • ZYME 446.6K
  • OSBC 199.2K
  • Earning Date
  • ZYME 10-30-2025
  • OSBC 10-15-2025
  • Dividend Yield
  • ZYME N/A
  • OSBC 1.31%
  • EPS Growth
  • ZYME N/A
  • OSBC N/A
  • EPS
  • ZYME N/A
  • OSBC 1.83
  • Revenue
  • ZYME $122,867,000.00
  • OSBC $282,178,000.00
  • Revenue This Year
  • ZYME $107.76
  • OSBC $24.92
  • Revenue Next Year
  • ZYME $2.35
  • OSBC $11.08
  • P/E Ratio
  • ZYME N/A
  • OSBC $9.98
  • Revenue Growth
  • ZYME 95.94
  • OSBC 6.55
  • 52 Week Low
  • ZYME $9.03
  • OSBC $14.14
  • 52 Week High
  • ZYME $17.70
  • OSBC $19.46
  • Technical
  • Relative Strength Index (RSI)
  • ZYME 64.90
  • OSBC 48.47
  • Support Level
  • ZYME $14.88
  • OSBC $18.22
  • Resistance Level
  • ZYME $16.37
  • OSBC $18.51
  • Average True Range (ATR)
  • ZYME 0.65
  • OSBC 0.34
  • MACD
  • ZYME 0.11
  • OSBC -0.04
  • Stochastic Oscillator
  • ZYME 84.12
  • OSBC 4.21

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About OSBC Old Second Bancorp Inc.

Old Second Bancorp Inc is a bank holding company. It provides consumer and commercial banking products such as demand, money market, savings, time deposit, and individual retirement as well as commercial, industrial, consumer, and real estate lending, including installment loans, student loans, agricultural loans, lines of credit and overdraft checking, safe deposit operations, trust services, wealth management services, and additional services tailored to the needs of individual customers, corporates, small-medium enterprises. The Company has one operating segment, which is community banking. The company's revenue consists of interest, commission, payments, and other income.

Share on Social Networks: